Amgen’s agreement with RNA interference specialist Arrowhead Pharmaceuticals will see it develop ...
September 30, 2016
Early data from the phase IIa trial of Arbutus’s hepatitis B RNA interference therapy ARB-1467 are ...
Welcome to your weekly digest of approaching regulatory and clinical readouts. By the end of the ...
September 27, 2016
September 01, 2016
August 25, 2016
August 15, 2016
August 03, 2016
Kite flies, but durability remains the key unknown
Event - Kite shoots, but what's the target?
Bubble stocks top the takeover premium charts
Esmo preview - Novel checkpoints add to the Parp showdown
EvaluatePharma World Preview 2016, Outlook to 2022
EP Vantage Pharma & Biotech Half-Year Review 2016
EP Vantage Medtech Half-Year Review 2016
EP Vantage Shifting CAR-Ts Into a Higher Gear
EP Vantage's 2016 Asco backgrounder
EP Vantage Pharma & Biotech 2015 in Review
EP Vantage Medtech 2015 in Review
EP Vantage Pharma & Biotech 2016 Preview
EP Vantage PD-1/PD-L1 Combination Therapies Report
EP Vantage Pharma & Biotech Half-Year Review 2015
EP Vantage Medtech Half-Year Review 2015
EP Vantage: Fewer, but bigger: medtech jobs jump thanks to mergers
EP Vantage: Mid-tier players make the most efficient employers
UK Biotech: A 10 Year Horizon
EvaluatePharma World Preview 2015, Outlook to 2020
Not for the Faint of CAR-T: The CAR-T Therapy Landscape in 2015
Terms & Conditions
Follow us on Twitter